SARASOTA, Fla., May 25 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (IBC), a company dedicated to new technologies and innovations in the chemicals industry, announced today that Dr. Kung-Ta Lee has accepted a position on IBC’s Scientific Advisory Board.
Dr. Lee is an Assistant Professor at National Taiwan University’s (NTU) Department of Biochemical Science and Technology; NTU’s Institute of Microbiology and Biochemistry and has previously served as Assistant Professor for NTU’s Department of Agricultural Chemistry. Dr. Lee was recently a Research Fellow at the Development Center of Biotechnology in Taipei, Taiwan and a Research Fellow at the Polyamine Co. in Taiwan. He has extensive expertise in plant cell culture, applied microbiology and industrial scale fermentation and purification processes.
“IBC is honored to include Dr. Kung-Ta Lee as a member of IBC’s highly qualified and respected team of Scientific Advisors,” said Mark Truei, Vice President of Production and Manufacturing for IBC. Mark continued, “Dr. Lee possesses the knowledge and experience necessary to execute the optimization, scale-up and commercialization of the numerous compounds in IBC’s pipeline scheduled for roll-out.”
“IBC’s intellectual property, patents and business model will have a far- reaching and positive effect with the changes that are taking place within the chemical industry,” said Dr. Lee. “I look forward to working with the members of IBC’s Scientific and Management Team and assisting with their continued development, growth and success.”
Dr. Lee received his Bachelor Degree in Agricultural Chemistry from National Taiwan University (1985 - 1989); Masters Degree in Agricultural Chemistry from National Taiwan University (1989 - 1991) and Doctorate in Biotechnology from The University of Tokyo (1995 - 1998). He currently serves as CEO for the Agricultural Chemical Society of Taiwan; Director for the Taiwan Association for Lactic Acid Bacteria and Editor for the Taiwan Bio Industry Organization.
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a higher purity and with a substantially lower environmental impact than traditional methods. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC seeks to bring to market new and established chemicals that are in high demand for use in flavors, fragrances, fine chemicals, pharmaceutical, agricultural, environmental and bio-energy applications. IBC’s pioneering and state-of-the- art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large commercial production levels. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and seeks to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable, biological-based solutions and related intellectual property patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward- looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact: Industrial Biotechnology Corporation Jack Hensley Vice President, Public & Investor Relations 2033 Main Street Sarasota, FL 34237 941-925-2500 jhensley@industrialbiotechnology.com
Industrial Biotechnology Corporation
CONTACT: Jack Hensley, Vice President, Public & Investor Relations,Industrial Biotechnology Corporation, +1-941-925-2500, orjhensley@industrialbiotechnology.com
Web site: http://www.industrialbiotechnology.com/
